Royal Bank Of Canada Akebia Therapeutics, Inc. Transaction History
Royal Bank Of Canada
- $471 Billion
- Q3 2024
A detailed history of Royal Bank Of Canada transactions in Akebia Therapeutics, Inc. stock. As of the latest transaction made, Royal Bank Of Canada holds 20,821 shares of AKBA stock, worth $43,307. This represents 0.0% of its overall portfolio holdings.
Number of Shares
20,821
Previous 20,066
3.76%
Holding current value
$43,307
Previous $20,000
35.0%
% of portfolio
0.0%
Previous 0.0%
Shares
12 transactions
Others Institutions Holding AKBA
# of Institutions
127Shares Held
57.4MCall Options Held
291KPut Options Held
179K-
Black Rock Inc. New York, NY11.6MShares$24.2 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.9MShares$22.6 Million0.0% of portfolio
-
State Street Corp Boston, MA6.3MShares$13.1 Million0.0% of portfolio
-
Satter Management Co., L.P.5.75MShares$12 Million13.23% of portfolio
-
Geode Capital Management, LLC Boston, MA4.8MShares$9.97 Million0.0% of portfolio
About Akebia Therapeutics, Inc.
- Ticker AKBA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 183,848,992
- Market Cap $382M
- Description
- Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...